Should I Buy HSCS? HSCS 2026 Analysis

Should You Buy HeartSciences Inc (HSCS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.210

1 Day change

-3.89%

52 Week Range

6.470

Analysis Updated At

2026/01/29

HSCS is not a good buy right now for a Beginner, long-term investor with $50,000–$100,000 who doesn’t want to wait for an optimal entry. The stock shows weakening technical momentum, there are no near-term catalysts/news, and the business fundamentals remain very small-scale with continued losses and worsening EPS year-over-year. I would stay on the sidelines (hold/avoid new buying).

Technical Analysis

Trend/Momentum: Bearish-to-neutral. The MACD histogram is -0.01 (below zero) and negatively expanding, which points to weakening momentum. RSI(6) at ~46.8 is neutral (not oversold), so there’s no clear “washed-out” bounce signal. Moving averages: Converging MAs suggest indecision/sideways action rather than a strong uptrend. Levels: Pivot 3.37 is above the last price (3.27), indicating price is currently trading below a key near-term equilibrium. Support sits at S1 3.122 then S2 2.968; resistance at R1 3.618 then R2 3.772. Near-term pattern odds: Similar-pattern analysis implies modest next-day upside (+0.42%) but negative bias over the next week (-5.37%) and month (-4.98%), aligning with the soft MACD. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Positive Catalysts

No news in the recent week, so no identifiable event-driven catalyst from the provided data.
Net loss improved YoY in the latest quarter (though still deeply negative).

Neutral/Negative Catalysts

No recent news/catalysts to attract fresh demand in the near term.
Technical momentum is weakening (MACD negative and expanding).
Pattern-based outlook is negative over the next week/month.
Business scale appears extremely small (very low revenue), with ongoing losses and EPS deterioration YoY.
No strong institutional/insider accumulation signals provided (both described as Neutral).

Financial Performance

Latest quarter: 2026/Q2. Revenue: 2,419 (up 0.00% YoY) — essentially flat and extremely small, indicating limited operating scale. Net income: -2,350,769 (improved 12.86% YoY) — losses narrowed but remain large. EPS: -0.85 (down -62.56% YoY) — per-share profitability worsened materially year-over-year. Gross margin: 58.33% (up 0.00% YoY) — stable margin, but the key issue is low revenue scale and continuing losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no observable recent trend in Wall Street ratings/targets to lean on. Wall Street pros (in principle): If adoption/sales accelerate, a small base could create high percentage growth; stable gross margin suggests the product economics could work at scale. Wall Street cons (dominant given provided data): Current revenue is extremely low, losses remain significant, and there are no listed catalysts or supportive trend signals; this combination typically keeps professional sentiment cautious. Politicians/Influential figures: No recent congress trading data available (no evidence of recent political buying/selling from the provided dataset). Congress trading (last 90 days): No recent congress trading data available.

2 Analyst Rating

Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.6 USD with a low forecast of 9.2 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.340

Low

9.2

Averages

10.6

High

Current: 3.340

Low

9.2

Averages

10.6

High

Ascendiant Capital

Lucas Ward

Strong Buy

Maintains

$15 → $14

AI Analysis

2025-03-18

Reason